These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38579004)

  • 1. Optical imaging reveals chemotherapy-induced metabolic reprogramming of residual disease and recurrence.
    Sunassee ED; Deutsch RJ; D'Agostino VW; Castellano-Escuder P; Siebeneck EA; Ilkayeva O; Crouch BT; Madonna MC; Everitt J; Alvarez JV; Palmer GM; Hirschey MD; Ramanujam N
    Sci Adv; 2024 Apr; 10(14):eadj7540. PubMed ID: 38579004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability.
    Sirois I; Aguilar-Mahecha A; Lafleur J; Fowler E; Vu V; Scriver M; Buchanan M; Chabot C; Ramanathan A; Balachandran B; Légaré S; Przybytkowski E; Lan C; Krzemien U; Cavallone L; Aleynikova O; Ferrario C; Guilbert MC; Benlimame N; Saad A; Alaoui-Jamali M; Saragovi HU; Josephy S; O'Flanagan C; Hursting SD; Richard VR; Zahedi RP; Borchers CH; Bareke E; Nabavi S; Tonellato P; Roy JA; Robidoux A; Marcus EA; Mihalcioiu C; Majewski J; Basik M
    Mol Cancer Res; 2019 Dec; 17(12):2492-2507. PubMed ID: 31537618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Response of Triple-Negative Breast Cancer to Folate Restriction.
    Coleman MF; O'Flanagan CH; Pfeil AJ; Chen X; Pearce JB; Sumner S; Krupenko SA; Hursting SD
    Nutrients; 2021 May; 13(5):. PubMed ID: 34068120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment.
    Baek ML; Lee J; Pendleton KE; Berner MJ; Goff EB; Tan L; Martinez SA; Mahmud I; Wang T; Meyer MD; Lim B; Barrish JP; Porter W; Lorenzi PL; Echeverria GV
    Oncogene; 2023 Mar; 42(14):1117-1131. PubMed ID: 36813854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
    Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
    FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
    Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
    Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance.
    Li S; Payne S; Wang F; Claus P; Su Z; Groth J; Geradts J; de Ridder G; Alvarez R; Marcom PK; Pizzo SV; Bachelder RE
    Breast Cancer Res; 2015 Jul; 17(1):91. PubMed ID: 26141457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of metformin on estrogen and progesterone receptor-positive (MCF-7) and triple-negative (MDA-MB-231) breast cancer cells.
    Amaral I; Silva C; Correia-Branco A; Martel F
    Biomed Pharmacother; 2018 Jun; 102():94-101. PubMed ID: 29550639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RIP1K and RIP3K provoked by shikonin induce cell cycle arrest in the triple negative breast cancer cell line, MDA-MB-468: necroptosis as a desperate programmed suicide pathway.
    Shahsavari Z; Karami-Tehrani F; Salami S; Ghasemzadeh M
    Tumour Biol; 2016 Apr; 37(4):4479-91. PubMed ID: 26496737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.
    Bush TL; Payton M; Heller S; Chung G; Hanestad K; Rottman JB; Loberg R; Friberg G; Kendall RL; Saffran D; Radinsky R
    Mol Cancer Ther; 2013 Nov; 12(11):2356-66. PubMed ID: 23990115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
    Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
    Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
    J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
    Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice.
    Fricke IB; De Souza R; Costa Ayub L; Francia G; Kerbel R; Jaffray DA; Zheng J
    PLoS One; 2018; 13(5):e0196892. PubMed ID: 29723251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
    Panayotopoulou EG; Müller AK; Börries M; Busch H; Hu G; Lev S
    Oncotarget; 2017 Jul; 8(28):45088-45104. PubMed ID: 28187446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
    Balko JM; Giltnane JM; Wang K; Schwarz LJ; Young CD; Cook RS; Owens P; Sanders ME; Kuba MG; Sánchez V; Kurupi R; Moore PD; Pinto JA; Doimi FD; Gómez H; Horiuchi D; Goga A; Lehmann BD; Bauer JA; Pietenpol JA; Ross JS; Palmer GA; Yelensky R; Cronin M; Miller VA; Stephens PJ; Arteaga CL
    Cancer Discov; 2014 Feb; 4(2):232-45. PubMed ID: 24356096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic reprogramming in triple-negative breast cancer.
    Wang Z; Jiang Q; Dong C
    Cancer Biol Med; 2020 Feb; 17(1):44-59. PubMed ID: 32296576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
    Kim MJ; Choi YK; Park SY; Jang SY; Lee JY; Ham HJ; Kim BG; Jeon HJ; Kim JH; Kim JG; Lee IK; Park KG
    Mol Cancer Res; 2017 Sep; 15(9):1230-1242. PubMed ID: 28584024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial adaptation decreases drug sensitivity of persistent triple negative breast cancer cells surviving combinatory and sequential chemotherapy.
    Winter M; Nait Eldjoudi A; Guette C; Hondermarck H; Bourette RP; Fovez Q; Laine W; Ghesquiere B; Adriaenssens E; Kluza J; Le Bourhis X
    Neoplasia; 2023 Dec; 46():100949. PubMed ID: 37956532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagy inhibition re-sensitizes pulse stimulation-selected paclitaxel-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis.
    Wen J; Yeo S; Wang C; Chen S; Sun S; Haas MA; Tu W; Jin F; Guan JL
    Breast Cancer Res Treat; 2015 Feb; 149(3):619-29. PubMed ID: 25638397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.